In our analysis, funnel plot examinations were performed for the following parameters: Tumor response: ORR, DCR; Safety profiles: overall adverse events, proteinuria, weakness, nausea/vomiting, diarrhea, hypertension, skin rashes, loss of appetite, reactive cutaneous capillary endothelial proliferation, gastrointestinal reaction, thrombocytopenia; Laboratory markers: AFP, ALB, ALT, AST; Immunological indicators: CD4+, CD8+; Clinical assessments: KPS; TCM outcomes: TCM syndrome composite scores, TCM syndrome efficacy scores (Figures 13A–V). This evidence concerns the gene CD8A and Hypertension.